Research ArticleClinical Studies
Efficacy and Toxicity of Pembrolizumab in Pediatric Metastatic Recurrent Melanoma
AGATA MARJANSKA, PRZEMYSLAW GALAZKA, MICHAL MARJANSKI, MARIUSZ WYSOCKI and JAN STYCZYNSKI
Anticancer Research July 2019, 39 (7) 3945-3947; DOI: https://doi.org/10.21873/anticanres.13547
AGATA MARJANSKA
1Department of Pediatric Hematology and Oncology, Nicolaus Copernicus University Torun, Jurasz University Hospital, Collegium Medicum, Bydgoszcz, Poland
PRZEMYSLAW GALAZKA
2Department of General and Oncological Surgery for Children and Adolescents, Nicolaus Copernicus University Torun, Jurasz University Hospital, Collegium Medicum, Bydgoszcz, Poland
MICHAL MARJANSKI
3Clinical Oncology Department, Oncology Center, Bydgoszcz, Poland
MARIUSZ WYSOCKI
1Department of Pediatric Hematology and Oncology, Nicolaus Copernicus University Torun, Jurasz University Hospital, Collegium Medicum, Bydgoszcz, Poland
JAN STYCZYNSKI
1Department of Pediatric Hematology and Oncology, Nicolaus Copernicus University Torun, Jurasz University Hospital, Collegium Medicum, Bydgoszcz, Poland
In this issue
Efficacy and Toxicity of Pembrolizumab in Pediatric Metastatic Recurrent Melanoma
AGATA MARJANSKA, PRZEMYSLAW GALAZKA, MICHAL MARJANSKI, MARIUSZ WYSOCKI, JAN STYCZYNSKI
Anticancer Research Jul 2019, 39 (7) 3945-3947; DOI: 10.21873/anticanres.13547
Jump to section
Related Articles
- No related articles found.